{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=16",
    "query": {
      "condition": "Hematologic Disease",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 10724,
    "total_pages": 1073,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:19:09.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00776373",
      "title": "Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ALL",
        "Burkitt's Lymphoma",
        "Lymphoblastic Leukemia",
        "CML"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "High dose etoposide and cytarabine (HiVAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2007-01",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00776373"
    },
    {
      "nct_id": "NCT01885897",
      "title": "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Myelodysplastic Syndromes (MDS)",
        "Lymphoma",
        "Myeloma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chronic Myelogenous Leukemia (CML)"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-11-11",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885897"
    },
    {
      "nct_id": "NCT03395210",
      "title": "A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Rilzabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Principia Biopharma, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2018-03-22",
      "completion_date": "2025-12-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 8,
      "location_summary": "Peoria, Illinois • Bethesda, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Midland",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03395210"
    },
    {
      "nct_id": "NCT00076180",
      "title": "Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Large Granular Lymphocytic Leukemia",
        "Leukemia, T-Cell Large Granular Lymphocytic"
      ],
      "interventions": [
        {
          "name": "Hu-MiK-Beta-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "2004-03-01",
      "completion_date": "2019-01-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-11",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00076180"
    },
    {
      "nct_id": "NCT00577096",
      "title": "Effects of Exercise in Combination With Epoetin Alfa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Autologous Peripheral Blood Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Red Blood Cell Transfusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Heparin, Low-Molecular-Weight",
          "type": "DRUG"
        },
        {
          "name": "Platelet Transfusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Therapy II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2001-10",
      "completion_date": "2004-06",
      "has_results": true,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577096"
    },
    {
      "nct_id": "NCT01786096",
      "title": "A Safety Study of SGN-CD19A for Leukemia and Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Burkitt Lymphoma",
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma"
      ],
      "interventions": [
        {
          "name": "SGN-CD19A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 92,
      "start_date": "2013-02",
      "completion_date": "2017-05-30",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786096"
    },
    {
      "nct_id": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma (NHL)",
        "Mantle Cell Lymphoma (MCL)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "8/12-Day Production of Car-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "8/12-Day Production of Cryopreserved Car-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "12-Day Production of Car-T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-05-18",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04186520"
    },
    {
      "nct_id": "NCT02675959",
      "title": "Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Defibrotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-07-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675959"
    },
    {
      "nct_id": "NCT00003003",
      "title": "Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mitomycin C",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 29,
      "start_date": "1996-09",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003003"
    },
    {
      "nct_id": "NCT00462761",
      "title": "A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Leukemia",
        "Myelodysplastic Syndrome",
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "AC220",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2007-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2020-05-11",
      "last_synced_at": "2026-11-15T14:19:09.416Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Omaha, Nebraska • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00462761"
    }
  ]
}